🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Canada / NCT06737224
Recruiting Not applicable

The Impact of a 48-hour Fast with or Without Exercise on Immune Cell Metabolism and Glycemic Control in Healthy Active Adults

NCT06737224 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2025-01-10
Last updated
2025-03-07

Condition(s) studied

FastingImmune FunctionGlucose Tolerance

Investigational drug(s) / intervention(s)

Fasting + Exercise (FAST+EX): fasting + exercise conditionFasting only (FAST): Non-exercise fasting condition

Fasting + Exercise (FAST+EX): fasting + exercise condition: Participants will complete a 48-hour fast. One hour of exercise will be performed on each morning of the fast.

Fasting only (FAST): Non-exercise fasting condition: Participant will complete a 48-hour fast. No structured exercise will be performed during each of the fasting days.

Study summary

Many individuals engage in fasting for its purported health benefits but the effects of fasting on immune cell and whole body metabolism are not well understood in humans. Moreover, how exercising during a prolonged fast impacts immunometabolic outcomes is unclear. This study will determine how a 2 day fast - performed with or without daily exercise - impacts immune cell bioenergetics, immune cell function, and whole-body glycemic control in healthy active individuals.

Eligibility

Sex
ALL
Min age
19 Years
Max age
35 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Aged between 19 and 35 years. * Physically active (engaging in ≥150 minutes of weekly moderate to vigorous physical activity). Exclusion Criteria: * History of cardiometabolic diseases or inflammatory diseases (e.g., chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, cardiovascular disease). * Individuals currently following a ketogenic diet, low-calorie diet, periodic fasting regimen, or consuming ketogenic supplements (e.g., exogenous ketone drinks). * Cigarette/vaping smoking. * Physical limitation that will impair the ability of the participant to perform exercise. * Individuals having a body mass index (BMI) over 30 kg/m2. * Cancer diagnosis in the past 5 years. * Taking anti-inflammatory drugs (e.g., ibuprofen, aspirin, naproxen). * Being unable to read or communicate in English.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of British Columbia Okanagan Campus Kelowna British Columbia Recruiting

More University of British Columbia trials in Canada

Other trials for the same condition

The Semaglutide Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06737224 on ClinicalTrials.gov ↗ ← All trials in Canada